Reovirus: A targeted therapeutic - Progress and potential

Molecular Cancer Research

Volumn 10, Issue 12, 2012, Pages 1514-1525

  Maitra, Radhashree ^a   Ghalib, Mohammad H ^a   Goel, Sanjay ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CASPASE 8; CISPLATIN; DOCETAXEL; GEMCITABINE; K RAS PROTEIN; MYTOMYCIN; NEUTRALIZING ANTIBODY; ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; PACLITAXEL; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VINBLASTINE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ACTIVATION; CELL DEATH; CELL MATURATION; CHILL; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DOSE ESCALATION; DRUG SAFETY; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOTENSION; INNATE IMMUNITY; LYMPHOCYTOPENIA; MELANOMA; NATURAL KILLER CELL; NEUTROPENIA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OPTIC NEURITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REOVIRUS; REVIEW; STOMACH CANCER; TUMOR REGRESSION; VIRUS REPLICATION;

ANIMALS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; REOVIRIDAE;

ORTHOREOVIRUS; RNA VIRUSES;

EID: 84871390091     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0157     Document Type: Review

References (82)

1. Sabin AB. Reoviruses. A new group of respiratory and enteric viruses formerly classified as ECHO type 10 is described. Science 1959;130:1387-9.
2. Nelson NJ. Viruses and cancer. J Natl Cancer Inst 1999;91:1709.
3. Min HJ, Koh SS, Cho IR, Srisuttee R, Park EH, Jhun BH, et al. Inhibition of GSK-3beta enhances reovirus-induced apoptosis in colon cancer cells. Int J Oncol 2009;35:617-24.
4. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001;93:903-12. (Pubitemid 32624647)
5. Van Den Wollenberg DJ, Van Den Hengel SK, Dautzenberg IJ, Kranenburg O, Hoeben RC. Modification of mammalian reoviruses for use as oncolytic agents. Expert Opin Biol Ther 2009;9:1509-20.
6. Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco LM, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther 2002;13:641-52. (Pubitemid 34264314)
7. Shmulevitz M, Marcato P, Lee PW. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 2005;24:7720-8. (Pubitemid 41670674)
8. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-4. (Pubitemid 28524498)
9. Mundschau LJ, Faller DV. Endogenous inhibitors of the dsRNA-dependent eIF-2 alpha protein kinase PKR in normal and ras-transformed cells. Biochimie 1994;76:792-800.
10. Hata Y, Etoh T, Inomata M, Shiraishi N, Nishizono A, Kitano S, et al. Efficacy of oncolytic reovirus against human breast cancer cells. Oncol Rep 2008;19:1395-8.
11. Errington F, White CL, Twigger KR, Rose A, Scott K, Steele L, et al. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 2008;15:1257-70.
12. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6. (Pubitemid 26353341)
13. Errington F, Steele L, Prestwich R, Harrington KJ, Pandha HS, Vidal L, et al. Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol 2008;180:6018-26.
14. Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J Exp Med 2002;195:F9-14.
15. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003;63:348-53. (Pubitemid 36152492)
16. Adair RA, Roulstone V, Scott KJ, Morgan R, Nuovo GJ, Fuller M, et al. Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med 2012;4:138ra77.
17. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351 -62.
18. Bischoff JR, Samuel CE. Mechanism of interferon action. Activation of the human P1/eIF-2 alpha protein kinase by individual reovirus s-class mRNAs: s1 mRNA is a potent activator relative to s4 mRNA. Virology 1989;172:106-15. (Pubitemid 19221441)
19. Park EH, Park EH, Cho IR, Srisuttee R, Min HJ, Oh MJ, et al. CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway. Cancer Gene Ther 2010;17:307-14.
20. Clarke P, Meintzer SM, Gibson S, Widmann C, Garrington TP, Johnson GL, et al. Reovirus-induced apoptosis is mediated by TRAIL. J Virol 2000;74:8135-9. (Pubitemid 30641660)
21. Twigger K, Vidal L, White CL, De Bono JS, Bhide S, Coffey M, et al. Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res 2008;14:912-23. (Pubitemid 351231176)
22. Barkett M, Gilmore TD. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999;18:6910-24.
23. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996;70:612-6. (Pubitemid 126508834)
24. Thirukkumaran CM, Shi ZQ, Luider J, Kopciuk K, Gao H, Bahlis N, et al. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res 2012;18:4962-72.
25. Gidwani P, Zhang W, Liu L, et al. Radiation in combination with Reolysin for pediatric sarcoma [Abstract]. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia, PA: AACR; 2008 Poster #3751.
26. Wadler S, Yu B, Lane M, Klampfer L, Sasazuki T, Shirasawa S, et al. The oncolytic reovirus, Reolysin augments the anticancer effects of cytotoxic agents in vitro against the ras-mutated human colon cancer cell line HCT116. European Journal of Cancer Supplements. 2004;8:135.
27. Lane M, Fahey J, Besanceney C, Hamel N, Yu B, Thompson B, et al. In vivo synergy between oncolytic reovirus and gemcitabine in ras-mutated human HCT-116 xenografts. [abstract]. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; 2007 Apr 14-18; Los Angeles, CA. Philadelphia, PA: AACR; 2007. Abstract nr. 4812.
28. Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, et al. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 2009;8:47.
29. Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, et al. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 2009;15:6158-66.
30. Gidwani P. Systemic administration of Reolysin inhibits growth of human sarcoma xenografts alone and in combination with cisplatin and radiation. Collective Tissue Oncology Society 2008;Poster # 35039.
31. Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, et al. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 2011;11:221.
32. Hashiro G, Loh PC, Yau JT. The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 1977;54:307-15. (Pubitemid 8167247)
33. Morris DG, Forsyth PA, Paterson AH, Fonseca K, Difrancesco LM, Thompson BG, et al. A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. Proc Am Soc Clin Oncol 21: 2002 (abstr 92)
34. Thirukkumaran CM, Nodwell MJ, Hirasawa K, Shi ZQ, Diaz R, Luider J, et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res 2010;70:2435-44.
35. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74. (Pubitemid 30303584)
36. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66. (Pubitemid 30303583)
37. Papanastassiou V, Rampling R, Fraser M, Petty R, Hadley D, Nicoll J, et al. The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Ther 2002;9:398-406. (Pubitemid 34414038)
38. Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 2004;11:1648-58. (Pubitemid 39530101)
39. Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, et al. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res 2010;16:3067-77.
40. Saunders M, Anthoney A, Coffey M, Mettinger K, Thompson B, Melcher A, et al. Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers. J Clin Oncol 27, 2009 (suppl; abstr e14514)
41. Gollamudi R, Ghalib MH, Desai KK, Chaudhary I, Wong B, Einstein M, et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 2010;28:641-9.
42. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-9. (Pubitemid 19213607)
43. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, et al. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005;7:413-21. (Pubitemid 41149657)
44. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 2008;14:7127-37.
45. White CL, Twigger KR, Vidal L, De Bono JS, Coffey M, Heinemann L, et al. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 2008;15:911-20. (Pubitemid 351791478)
46. Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, et al. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer 2011;11:221.
47. Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS. Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev 2010;21:91-8.
48. Lolkema MP, Arkenau HT, Harrington K, Roxburgh P, Morrison R, Roulstone V, et al. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 2011;17:581-8.
49. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002;62:2353-8. (Pubitemid 34411717)
50. Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008;14:7358-66.
51. Plate JM, Plate AE, Shott S, Bograd S, Harris JE. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 2005;54:915-25. (Pubitemid 40991334)
52. Mita M, Wang Y, Sarantopoulos J, Vemulapalli S, George B, Mita A, et al. A Study of REOLYSIN® in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma. In: Proceedings of the AACR-NCIEORTC International Conference on Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr B55.
53. Maddox JF, Amuzie CJ, Li M, Newport SW, Sparkenbaugh E, Cuff CF, et al. Bacterial- and viral-induced inflammation increases sensitivity to acetaminophen hepatotoxicity. J Toxicol Environ Health A 2010;73:58-73.
54. Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 2010;16:5564-72.
55. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14:3536-44.
56. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, et al. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 2012;18:2080-9.
57. Karnad A, Haigentz M, Miley T, Coffey M, Gill G, Mita M. A Phase II Study of Intravenous Wild-type Reovirus (REOLYSIN®) in Combination with Paclitaxel Plus Carboplatin in Patients with Platinum Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr C22.
58. Villalona-Calero MA, Lam ET, Otterson GA, Donthireddy KR, Thurmond J, Hade E, et al. Phase II study of reovirus with paclitaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC) who have Kras or EGFR-activated tumors. 14th World Lung Cancer Congress, (suppl; abstr MO15.08) 2011.
59. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res. 2008;14:259- 69.
60. Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM. Gemcitabine selectively eliminates splenic Gr-1+/CD11b +myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21. (Pubitemid 41339014)
61. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101-17. (Pubitemid 46189539)
62. Csatary LK. Viruses in the treatment of cancer. Lancet 1971;2:825.
63. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer cell 2004;6:611-23. (Pubitemid 40017704)
64. Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst 2006;98:298-300.
65. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, et al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]. Ai Zheng 2004;23:1666-70.
66. Coffin RS, Hu JC, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. Results of a Phase I/II clinical trial with OncoVEXGM-CSF, a second generation oncolytic herpes simplex virus. J Clin Oncol 2005;23, No. 16S, Part I of II (June 1 Supplement), 3099.
67. Harrington K, Hingorani M, Tanay M, Hickey J, Bhide SA, Clarke PM, et al. Phase I/II dose escalation study of OncoVexGM-CSF and chemoradiotherapy (CRT) in untreated stage III/IV squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 27:15s, 2009(suppl; abstr 6018).
68. Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK, et al. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 2007;14:756-61. (Pubitemid 47080367)
69. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-66. (Pubitemid 34441652)
70. Giedlin MA, Cook DN, Dubensky TW Jr. Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology? Cancer Cell 2003;4:241-3. (Pubitemid 37329785)
71. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003;4:263-75. (Pubitemid 37329791)
72. Stewart JH IV, Ahmed M, Northrup SA, Willingham M, Lyles DS. Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther 2011;18:837-49.
73. Bridle BW, Boudreau JE, Lichty BD, Brunellière J, Stephenson K,Koshy S, et al. Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus. Mol Ther 2009;17:1814-21.
74. Hasegawa K, Nakamura T, Harvey M, Ikeda Y, Oberg A, Figini M, et al. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res 2006;12:6170-8. (Pubitemid 44703783)
75. Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, et al. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat 2010;122:745-54.
76. Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009;330:213-41.
77. Bell J. Oncolytic viruses: an approved product on the horizon? Mol Ther 2010;18:233-4.
78. Wong HH, Lemoine NR, Wang Y. Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses 2010;2:78-106.
79. Zeyaullah M, Patro M, Ahmad I, Ibraheem K, Sultan P, Nehal M, et al. Oncolytic viruses in the treatment of cancer: a review of current strategies. Pathol Oncol Res 2012;18:771-81.
80. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
81. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15. (Pubitemid 351325672)
82. Seetharam R, Coffey M, Klampfer L, Mariadason J, Goel S. The addition of Reolysin, an oncolytic reovirus, to irinotecan shows synergistic anti cancer activity in colorectal cancer cell lines [Abstract]. In: Proceedings of the 101st Annual Meeting of the American Association of Cancer Research, 2010 Mar 31-April 3; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract nr # 1773.